Autofluorescence imaging resolves early cancer treatment response in vivo

Alex Walsh, Rebecca S. Cook, H. Charles Manning, Donna J. Hicks, Alec Lafontant, Carlos L. Arteaga, Melissa C. Skala

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.

Original languageEnglish (US)
Title of host publicationOptical Molecular Probes, Imaging and Drug Delivery, OMP 2013
PagesMT3C.5
StatePublished - Nov 19 2013
EventOptical Molecular Probes, Imaging and Drug Delivery, OMP 2013 - Waikoloa Beach, HI, United States
Duration: Apr 14 2013Apr 18 2013

Publication series

NameOptical Molecular Probes, Imaging and Drug Delivery, OMP 2013

Other

OtherOptical Molecular Probes, Imaging and Drug Delivery, OMP 2013
CountryUnited States
CityWaikoloa Beach, HI
Period4/14/134/18/13

    Fingerprint

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Atomic and Molecular Physics, and Optics

Cite this

Walsh, A., Cook, R. S., Manning, H. C., Hicks, D. J., Lafontant, A., Arteaga, C. L., & Skala, M. C. (2013). Autofluorescence imaging resolves early cancer treatment response in vivo. In Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013 (pp. MT3C.5). (Optical Molecular Probes, Imaging and Drug Delivery, OMP 2013).